Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025, at 8:30 a.m. Eastern Time to discuss the September 4 Contractor Advi ...

Key Takeaways Hologic's Panther Fusion boosts growth with more than 20 approved assays and strong global adoption.BV, CV/TV test has become Hologic's second-largest assay, with large untapped U.S. testing potential.One-third of HOLX customers use Fusion, with new assays and premium pricing set to drive future expansion.Hologic’s (HOLX) fully automated, high-throughput Panther platform remains the foundation of its molecular diagnostics business. The Panther Fusion module, a 2016 addition to the base system, ...

Question-and-Answer SessionBrandon CouillardWells Fargo Securities, LLC, Research Division Never short of things to talk about when it comes to Exact. We'll get to all those things. I do want to just kind of focus on maybe to start with fundamentals in 2Q, which were kind of overshadowed by Freenome from which we'll get to, of course, Cologuard growth accelerated for the second straight quarter, you're up like 18% year-over-year. Guide implies you kind of exit the year at a high teens clip. Cologuard Plus p ...

BERKELEY, Calif. and MAINZ, Germany, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert® has received official registration with the Medicines and Healthcare products Regulatory Agency (MHRA) and is now authorized for marketing in the United Kingdom. This milestone follows the technology partnership announced earlier this year with EDX Medic ...

Core Viewpoint - Biomerica, Inc. reported a modest decline in net sales for fiscal year 2025, attributed to global tariff uncertainties and a shift in product mix, but achieved significant improvements in operating efficiency and cost management [2][3][5]. Financial Performance - Net sales for fiscal year 2025 were $5.3 million, slightly down from $5.4 million in the previous year [2][6]. - Gross profit decreased to $498,000 from $611,000, reflecting macroeconomic impacts [3][6]. - Operating loss improved to $5.1 million, a 19% year-over-year improvement from $6.4 million [5][6]. - Cash used in operating activities reduced to $3.8 million from $5.3 million, indicating stronger operational discipline [3][8]. - Total operating expenses decreased to $5.6 million from $7.0 million, with significant reductions in selling, general, and administrative expenses as well as research and development costs [4][6]. Strategic Growth Areas - Biomerica is focusing on three key areas for revenue growth, including advancements in its inFoods IBS diagnostic product [7]. - The company submitted a Proprietary Laboratory Analyses (PLA) code application for inFoods IBS, which has received approval, enhancing reimbursement pathways [7][9]. - The company is expanding its product offerings in the MENA region and pursuing insurance reimbursement for new products [9][11]. Product Development and Innovation - The inFoods IBS test has shown statistically significant clinical improvements in patient outcomes, with a new self-collection system introduced for easier access [10][13][16]. - Biomerica achieved EU IVDR certification for its food-intolerance diagnostic tests, supporting future commercialization in Europe [10]. - The company has been granted three new international patents related to its inFoods technology platform [12]. Market Expansion - Biomerica has expanded its footprint in the Middle East with the approval of its Fortel PSA rapid screening test by the UAE Ministry of Health [11]. - The company launched direct-to-consumer availability of inFoods IBS, broadening patient access through telehealth and digital channels [11].

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [3] - The company focuses on patients with GERD (chronic heartburn) who are at risk of developing esophageal precancer and cancer [3]. Product Information - Lucid's flagship product is the EsoGuard® Esophageal DNA Test, which is performed using the EsoCheck® Esophageal Cell Collection Device [3]. - These tools are designed for the early detection of esophageal precancer in at-risk patients, aiming to prevent esophageal cancer and related deaths [3]. Upcoming Event - Lishan Aklog, M.D., Chairman and CEO of Lucid, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on September 5, 2025, at 8:35 AM EDT [1][2]. - The event will be available via live and archived webcast, accessible through the company's Investor Relations section [2].

Core Viewpoint - IDEXX Laboratories (IDXX) has shown strong momentum in 2025, with shares rising 56.2%, significantly outperforming the industry decline of 6.8% and the S&P 500 increase of 9.8% [1] Group 1: Company Performance - IDEXX develops and distributes products and services primarily for the companion animal veterinary, livestock, poultry, water testing, and dairy markets, along with portable medical diagnostics for human care [2] - The company reported an 11% organic rise in international CAG diagnostic recurring revenues in Q2 2025, driven by strong global performance [3] - IDEXX's VetLab consumable organic revenue growth was bolstered by robust double-digit growth in international regions [4] Group 2: Growth Drivers - Investors are focusing on IDEXX's cloud-based software solutions, which enhance clinic workflows and diagnostics utilization, with double-digit growth in platforms like ezyVet and Neo [5] - The financial outlook for 2025 has been raised, with total revenues expected to be between $4.21 billion and $4.28 billion, indicating a growth of 7.7-9.7% [6] - The operating profit for Q2 rose 541.4% year over year to $373.1 million, contributing to an operating margin expansion of 734 basis points [7] Group 3: Market Position - IDEXX's international CAG diagnostic revenues increased by 11% in Q2, with strong gains in consumables [9] - The Zacks Consensus Estimate for 2025 EPS has increased by 2.8% to $12.55 in the past 30 days, with an earnings yield of 1.9% compared to the industry's -4.8% [12]

Group 1: Zacks Premium Overview - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] - The service also includes Zacks Style Scores, which are designed to help investors identify stocks with the best potential to outperform the market in the short term [2] Group 2: Zacks Style Scores - Zacks Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each providing insights into different investment strategies [3][4][5][6] - The Value Score focuses on identifying undervalued stocks using financial ratios, while the Growth Score emphasizes a company's financial health and future growth potential [3][4] - The Momentum Score helps investors capitalize on price trends, and the VGM Score combines all three styles to highlight stocks with the best overall characteristics [5][6] Group 3: Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist in stock selection, with 1 (Strong Buy) stocks achieving an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [7][8] - There are over 800 stocks rated as 1 or 2, making it essential for investors to utilize Style Scores to narrow down their choices [9][10] Group 4: Stock Highlight - IDEXX Laboratories - IDEXX Laboratories, Inc. is a company focused on products and services for veterinary, livestock, water testing, and human diagnostics markets, currently holding a 3 (Hold) Zacks Rank with a VGM Score of B [12] - The company has a Momentum Style Score of A, with shares increasing by 15.1% in the past four weeks, and analysts have raised earnings estimates for fiscal 2025 [13] - The Zacks Consensus Estimate for IDEXX's earnings has risen by $0.39 to $12.55 per share, indicating a positive outlook for the company [13]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sco ...

Core Insights - Hologic (HOLX) is a leader in the cytology sector, focusing on cervical cancer screening with innovative products like the ThinPrep Pap test and the Aptima HPV Assay [1][2] - The introduction of the Genius digital cytology system, the first FDA-cleared platform combining AI and advanced imaging, is expected to drive growth despite recent sales challenges in China [2][7] - Hologic's Cytology business has historically seen modest growth, but the Genius system is anticipated to enhance efficiency and address labor shortages, making it a multi-year growth driver [3][7] Company Developments - The Genius system replaces traditional manual slide reviews with digital imaging, allowing remote access and improving workflow in labs [3] - Hologic's management indicated that without the sales headwinds in China, the Cytology business would have experienced low single-digit growth in Q2 FY25, instead of a reported decline of 2.2% [2][7] - The rollout of the Genius system is expected to take several years, contributing to future growth [3] Competitive Landscape - Quest Diagnostics (DGX) has introduced a new HPV screening solution to expand access, allowing specimen collection in various healthcare settings [4] - Roche offers a comprehensive cervical cancer testing portfolio, including the cobas HPV test and CINtec tests, which are FDA-approved for various screening indications [5] Stock Performance and Valuation - Hologic's stock has increased by 5.2% over the past six months, contrasting with an 11.9% decline in the industry [6] - The company is trading at a forward three-year price-to-earnings ratio of 15.23X, significantly lower than the industry average of 28.67X [8] - Consensus estimates for Hologic's fiscal 2025 earnings show stability, with current estimates at $4.22 per share [10]